Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment

PURPOSE: The safety and efficacy of subcutaneous immune globulin 20% (human) solution (Ig20Gly) were demonstrated in clinical trials. However, real-world evidence of the tolerability of self-administered Ig20Gly in elderly patients is lacking. We describe real-world patterns of Ig20Gly usage for 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenbach, Kevin, Park, Michelle, Sanchirico, Marie, Nwose, Oliseyenum, Paris, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275800/
https://www.ncbi.nlm.nih.gov/pubmed/36809598
http://dx.doi.org/10.1007/s10875-023-01436-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275800/
https://www.ncbi.nlm.nih.gov/pubmed/36809598
http://dx.doi.org/10.1007/s10875-023-01436-4

Ejemplares similares